Daily pill helps patients lose 12% of body weight in early trial | Diets and dieting

It has been shown that a daily weight loss pill helps patients lose around 12% of their body weight, according to the results of a clinical trial.

The drug, manufactured by the American pharmaceutical company Eli Lilly, is a GLP -1 agonist – a type of medication that helps reduce blood sugar, reduces appetite and slows digestion.

More than 3,000 people participated in the 72 -week study. Those who received the highest dose – 36 mg of Orforglipron – lost an average of 12.4% of their body weight, against only 0.9% of the control group.

The trial has also shown other health benefits for users, including cholesterol improvements, blood pressure and the risk of heart disease.

The results occur after the Novo Nordisk Oral Weight Loss Medication, which was submitted for approval in the United States, helped the participants in the trial to lose around 15% of their body weight.

Eli Lilly manufactures Mounjaro, an injection once a week which contains medication shooting, which is also used to help improve blood sugar in people with type 2 diabetes.

A weight loss pill could offer a more practical and cheaper alternative – for patients and the NHS – injectable treatments during deployment through England.

The test has not yet been examined by peers and its results are preliminary.

Kenneth Custer, President of Eli Lilly, said: “With Orforglipron, we are working to transform obesity care by introducing potential oral therapy once a day which could support early intervention and long -term disease management, while providing a practical alternative to injection treatments.

“With these positive data in hand, we now plan to subject Orforglipron for a regulatory examination by the end of the year and are prepared for a global launch to meet this urgent need of public health.”

Dr. Simon Cork, lecturer in physiology at Anglia Ruskin University, said that although the preliminary results of efficiency are a “positive step”, they should be interpreted with caution.

He said: “It should be noted that their effects on weight loss are not as deep as those observed in injectable GLP-1 receptors, such as Wegovy, with a percentage of lower weight loss and fewer people reaching 10% of weight loss in the highest dose.

“It should be noted that these are preliminary and not examined results and we will have to see the methodology and complete test data before a more complete analysis can be undertaken.”